https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30063 50 μM across all cell lines, with the 2-OH-Ph substituted 12l analogue presenting with sub-micromolar potency against the A2780 (ovarian; 0.34 ± 0.04 μM), BEC-2 (glioblastoma; 0.35 ± 0.06 μM), MIA (pancreas; 0.91 ± 0.054 μM) and SMA (murine glioblastoma; 0.77 ± 0.029 μM) carcinoma cell lines. Interestingly, the U87 glioblastoma cell line showed inherent resistance to growth inhibition by all analogues (GI50 32 to >50 μM) while the A2780 cells were highly sensitive (GI50 3.8–0.34 μM), suggesting that the analogues developed herein may be valuable lead compounds for the development of ovarian carcinoma specific cytotoxic agents. The differences in amide versus ester cytotoxicity was consitent with esterase cleaveage to release the cytotoxic warhead.]]> Wed 11 Apr 2018 11:15:48 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49939 Wed 06 Mar 2024 14:38:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27394 Sat 24 Mar 2018 07:34:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:3852 Sat 24 Mar 2018 07:19:57 AEDT ]]>